StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30511% above fair value
$195.00−4.33 (-2.17%)

Close on Nov 20, 2026Market cap $77.85BP/E –Yield –

Moderna free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Moderna's free cash flow for the twelve months ending Jun 30, 2026 was -$1.24B. For fiscal 2025 it was -$2.07B. The highest annual figure on record is $13.34B in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.07B–
FY2024Dec 31, 2024-$4.06B–
FY2023Dec 31, 2023-$3.83B-183.5%
FY2022Dec 31, 2022$4.58B-65.6%
FY2021Dec 31, 2021$13.34B+580.8%
FY2020Dec 31, 2020$1.96B–
FY2019Dec 31, 2019-$491.00M–
FY2018Dec 31, 2018-$436.63M–
FY2017Dec 31, 2017-$389.89M-1260.7%
FY2016Dec 31, 2016$33.59M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$563.00M–
Q1 FY2026Mar 31, 2026-$692.00M–
Q4 FY2025Dec 31, 2025$891.00M+194.1%
Q3 FY2025Sep 30, 2025-$880.00M–
Q2 FY2025Jun 30, 2025-$922.00M–
Q1 FY2025Mar 31, 2025-$1.15B–
Q4 FY2024Dec 31, 2024$303.00M-24.6%
Q3 FY2024Sep 30, 2024-$1.72B–
Q2 FY2024Jun 30, 2024-$1.46B–
Q1 FY2024Mar 31, 2024-$1.19B–
Q4 FY2023Dec 31, 2023$402.00M-74.4%
Q3 FY2023Sep 30, 2023-$1.74B-1167.5%
Q2 FY2023Jun 30, 2023-$1.15B-629.5%
Q1 FY2023Mar 31, 2023-$1.34B-150.9%
Q4 FY2022Dec 31, 2022$1.57B-50.8%
Q3 FY2022Sep 30, 2022$163.00M-94.9%
Q2 FY2022Jun 30, 2022$217.00M-94.6%
Q1 FY2022Mar 31, 2022$2.63B-10.4%
Q4 FY2021Dec 31, 2021$3.19B+157.3%
Q3 FY2021Sep 30, 2021$3.18B+263.5%
Q2 FY2021Jun 30, 2021$4.03B–
Q1 FY2021Mar 31, 2021$2.94B–
Q4 FY2020Dec 31, 2020$1.24B–
Q3 FY2020Sep 30, 2020$874.00M–
Q2 FY2020Jun 30, 2020-$43.00M–
Q1 FY2020Mar 31, 2020-$112.00M–
Q4 FY2019Dec 31, 2019-$106.16M–
Q3 FY2019Sep 30, 2019-$113.80M–
Q2 FY2019Jun 30, 2019-$119.17M–
Q1 FY2019Mar 31, 2019-$151.86M–
Q4 FY2018Dec 31, 2018-$104.66M–
Q3 FY2018Sep 30, 2018-$106.35M–
Q2 FY2018Jun 30, 2018-$82.33M–
Q1 FY2018Mar 31, 2018-$143.29M–

More Moderna figures

See a number that looks wrong?